IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-09	HK$12.68	-0.16%	3,225,800
26-10-08	HK$12.70	-12.35%	2,649,000
26-10-07	HK$14.49	+1.40%	321,000
26-10-06	HK$14.29	+2.07%	259,400
26-10-05	HK$14.00	-1.48%	222,000

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

10.82CNY

Average target price

27.28CNY

Spread / Average Target

+152.04%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IMPACT Therapeutics, Inc

Company calendar

Market Closed - Hong Kong S.E. 04:08:08 2026-10-09 EDT			5-day change	1st Jan Change
12.68 ^HKD	-0.16%		-10.77%	-

09-18	IMPACT Therapeutics And Pharmanovia Receive Positive CHMP Opinion For Senaparib As First-Line Maintenance Treatment Of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer	CI
09-18	Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug	MT

Market Cap	3.06B 3.58B 456M 408M 379M 345M 651M 44.17B 654M 4.56B 1.79B 22.52B 1.71B 1.68B 72.27B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.24B 2.63B 335M 299M 278M 253M 477M 32.37B 479M 3.34B 1.31B 16.51B 1.26B 1.23B 52.97B	EV / Sales 2026 *	8.46x	EV / Sales 2027 *	3.26x
Free-Float	53.09%	Yield 2026 *	-	Yield 2027 *	-

09-18	IMPACT Therapeutics And Pharmanovia Receive Positive CHMP Opinion For Senaparib As First-Line Maintenance Treatment Of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer	CI
09-18	Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug	MT
09-07	Impact Therapeutics Joins Shenzhen-and Shanghai-Hong Kong Stock Connect Programs	MT
09-03	Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%	MT
09-03	Impact Therapeutics CEO Boosts Shareholding	MT
08-31	IMPACT Therapeutics, Inc Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-23	IMPACT Therapeutics to Join Hang Seng Composite Index	MT
08-12	Impact Therapeutics Announces IMP2794 as A Preclinical Candidate, A Highly Kat6a-Specific PROTAC from Its Proprietary Targeted Protein Degradation Platform	CI
08-11	IMPACT Therapeutics, Inc. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
07-31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
07-27	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
07-27	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
07-20	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI

1 day	-0.16%
1 week	-10.77%
Current month	-9.88%
1 month	+9.12%
3 months	-34.97%

IMPACT Therapeutics, Inc Stock

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news: IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Price Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 week	11.84	14.76
1 month	11	20.56
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	2014-05-31
Hui Jun Deng DFI	Director of Finance/CFO	51	2024-04-30
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	2024-12-31

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	2014-05-31
Sui Xiong Cai BRD	Director/Board Member	69	2014-05-31
Ning Ma BRD	Director/Board Member	44	2025-02-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	-0.16%	-10.77%	-	-	456M
WUXI APPTEC CO., LTD.	-2.59%	-5.70%	+50.69%	+86.86%	70.61B
ARGENX SE	+3.23%	-10.67%	+6.27%	+53.70%	51.01B
LONZA GROUP AG	+1.56%	+1.17%	+8.49%	+31.81%	48.1B
IQVIA HOLDINGS INC.	+0.39%	+0.65%	+31.14%	+28.97%	42.78B
REVOLUTION MEDICINES, INC.	+0.87%	-8.17%	+293.37%	+642.41%	40.67B
BEONE MEDICINES AG	+1.24%	-1.01%	+10.74%	+100.64%	40.3B
CELLTRION, INC.	-2.13%	-1.64%	+8.63%	+46.88%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.46%	-1.28%	+42.23%	+20.34%	28.16B
BIONTECH SE	+5.32%	+0.06%	-5.00%	-12.78%	24.36B
Average	+0.73%	-3.47%	+49.62%	+110.98%	37.7B
Weighted average by Cap.	+0.56%	-2.95%	+51.35%	+115.57%

	2026 *	2027 *
Net sales	265M 310M 39.53M 35.31M 32.84M 29.87M 56.4M 3.83B 56.65M 395M 155M 1.95B 148M 145M 6.26B	630M 738M 94M 83.95M 78.1M 71.04M 134M 9.1B 135M 940M 368M 4.64B 353M 345M 14.88B
Net income	-	-
Net Debt	-816M -957M -122M -109M -101M -92.11M -174M -11.8B -175M -1.22B -478M -6.01B -458M -448M -19.3B	-1.01B -1.18B -150M -134M -125M -113M -214M -14.53B -215M -1.5B -588M -7.41B -564M -552M -23.78B